Macquarie expects the company to report healthy EBITDA margin in the 26-27 percent range in H2 and raises FY22-24 EPS estimates by 3-10 percent.īroking house Citi has maintained buy call and raised the target to Rs 1,000. There was a beat on PAT even higher due to a low tax rate. Macquarie kept an outperform call and raised the target to Rs 964 from Rs 925 after the company delivered a solid Q2 surpassing the EBITDA estimate by 8 percent. The company is well placed to boost specialty sales & achieve EBITDA breakeven in FY23 and raise the earnings estimates 4-11 percent over 22-24. It was another quarterly margin surprise that drove a Q2 result beat. Research firm has maintained buy call and raised the target price to Rs 1,050 per share as specialty ramp-up is on track & earnings upgrades to continue.
The company turned net cash even on ex-Taro and repaid debt of USD 209 million in H1FY22.Ĭredit Suisse has lifted FY22/FY23/FY24 EPS by 6%/2%/3%.
SUN PHARMA MONEYCONTROL DRIVERS
The specialty ramp-up, balance sheet strengthening & potential Halol remediation drivers for re-rating.īroking firm has maintained an underperform call and raised the target price to Rs 695. The company continues to show broad-based growth across India, US, EMs & RoW and expect margin to continue to improve. Unlocking opportunities in Metal and Mining.Interview Series Business In The Week Ahead.
0 kommentar(er)
